

## Notice of Acceptance for European Patent

PainChek® Ltd (ASX: PCK) (“PainChek®” or “the Company”), developer of the world’s first smart phone-based pain assessment and monitoring application, is pleased to announce that the European Patent Office (EPO) has issued a Notice of Acceptance for its patent application No. 15833312.0.

The patent application, entitled "A Pain Assessment Method and System", will enable PainChek to safeguard the intellectual property of its pain assessment and monitoring technology within the European market. This includes exclusive rights to the commercialisation of its technology across the 39 member states of the European Patent Organisation.

PainChek's CEO Philip Daffas said: "This acceptance letter is the precursor to a fully granted patent, securing our intellectual property in the significantly large European markets which is key to our global strategy, including the UK where we continue to demonstrate growing adoption of PainChek. This new patent is in addition to the existing patents granted in the USA, Japan, and China providing intellectual property protection of our technology across the largest healthcare markets in the world."

The patent protection for all these regions is until 2035.

The Company expects to receive the formal grant of the patent in the near term, subsequent to the finalisation of final paperwork and administrative procedures with the EPO.

This release has been authorised for release by PainChek CEO Philip Daffas.

### For more information:

Lisa Dadswell

Company Secretary, PainChek

[lisa.dadswell@boardroomlimited.com.au](mailto:lisa.dadswell@boardroomlimited.com.au)

02 8016 2819

Philip Daffas

CEO, PainChek

[philip.daffas@painchek.com](mailto:philip.daffas@painchek.com)

0406 537 235

### About PainChek®

PainChek® Ltd is an Australian based company that develops pain assessment technologies.

Pain often goes unrecognised and under-treated in people with communication difficulties. PainChek Universal is a clinically validated smartphone-based medical device that enables best practice pain assessment for all people, everywhere.

PainChek Universal is a complete point-of-care solution that combines the existing PainChek® App with the Numerical Rating Scale (NRS). This enables best-practice pain management for all residents living with pain in any environment — from those who cannot verbalise pain to those who can, and those who fluctuate between the two.

The PainChek® App uses artificial intelligence and facial recognition to detect pain in those who cannot self-report. This gives a voice to those who cannot verbalise pain, whilst also driving objectivity and consistency in all assessments. For those who can self-report, PainChek Universal also includes access to the Numerical Rating Scale, a well-established standard used to document pain levels amongst these individuals. PainChek Universal also supports pain assessment using both tools at the point of care, for those people whose ability to communicate fluctuates.

PainChek® is being rolled out globally in two phases: first, PainChek® for adults who are unable to effectively verbalise their pain such as people with dementia, and second, PainChek® for infants who have not yet learnt to speak. Both the adult and infants products have received regulatory clearance in numerous markets including Australia, Europe, UK, NZ, Singapore and Canada.

The PainChek® Shared Care Program is a PainChek® licensing model which enables a professional carer to share their resident or patient data securely with other healthcare professionals or designated homebased family carers for ongoing pain assessments or clinical data review.

To find out more, visit [www.painchek.com](http://www.painchek.com)